Physician profile
Kanwardeep S Aiden
NPI 1336109875
$5,776.75
in general payments reported to CMS, 2019-2025
25 companies · $663 in 2025
The $663 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $669 · 2021: $1,034 · 2022: $705 · 2023: $817 · 2024: $911 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,497.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $731.86 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $549.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.06 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $383.90 | 2019-2022 | |
| Amarin Pharma, INC. | $358.95 | 2019-2021 | |
| Novo Nordisk INC | $325.38 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $300.73 | 2021-2025 | Vraylar |
| Pfizer INC. | $226.79 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $132.72 | 2019-2024 | Lagevrio |
| Amgen INC. | $82.42 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $71.36 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $65.22 | 2023-2025 | Cologuard Collection Kit |
| Indivior INC. | $60.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $55.07 | 2020-2024 | Nexletol |
| Genentech USA, INC. | $53.01 | 2019-2021 | |
| Allergan, INC. | $49.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.90 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $37.13 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $36.74 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.65 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.51 | 2024 | |
| Hikma Pharmaceuticals USA | $13.42 | 2021 | |
| Eisai INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanwardeep Aiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.